SeraCare A.I CyberSecurity Scoring
06/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for SeraCare in 2026.
No incidents recorded for SeraCare in 2026.
No incidents recorded for SeraCare in 2026.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Latest updates, reports, and threat intel affecting the global network.
A vulnerability was detected in D-Link DIR-825M 1.1.8. This affects the function sub_46725C of the file /boafrm/formDiskFormat of the component Disk Formatting Handler Endpoint. The manipulation of the argument partition results in stack-based buffer overflow. The attack can be executed remotely. The exploit is now public and may be used.
A security vulnerability has been detected in Open Asset Import Library Assimp up to 6.0.2. The impacted element is the function MD5Importer::MakeDataUnique of the file code/AssetLib/MD5/MD5Loader.cpp. The manipulation of the argument iNewIndex leads to heap-based buffer overflow. The attack can only be performed from a local environment. The identifier of the patch is bf9dabb617c46e5133dac65cca6bff177917afcb. Applying a patch is the recommended action to fix this issue.
A weakness has been identified in Open5GS up to 2.7.7. The affected element is the function smf_nudm_sdm_handle_get of the file src/smf/nudm-handler.c of the component SMF. Executing a manipulation of the argument preemptCap can lead to reachable assertion. The attack may be launched remotely. Upgrading to version 2.8.0 is sufficient to fix this issue. This patch is called 4554405f29bffd7562abedbee63484825bd90cd5. You should upgrade the affected component.
A security flaw has been discovered in Open5GS up to 2.7.7. Impacted is the function amf_namf_comm_handle_n1_n2_message_transfer of the file src/amf/namf-handler.c of the component N1-N2 Message Handler. Performing a manipulation of the argument N1N2MessageTransferReqData.n2InfoContainer.smInfo.n2InfoContent.ngapIeType results in denial of service. The attack may be initiated remotely. The exploit has been released to the public and may be used for attacks. Upgrading to version 2.8.0 is recommended to address this issue. The patch is named abf8a836564b966b5141110fc25ed413c4f17522. It is advisable to upgrade the affected component.
A vulnerability was identified in Open5GS up to 2.7.7. This issue affects some unknown processing of the file src/amf/namf-handler.c of the component Transfer Endpoint. Such manipulation leads to null pointer dereference. The attack can be launched remotely. Upgrading to version 2.8.0 is capable of addressing this issue. The name of the patch is abf8a836564b966b5141110fc25ed413c4f17522. Upgrading the affected component is advised.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.